28.09.2017 • Topics

M&A in Pharma and CRO/CMO Industry

(c) cacaroot/Fotolia
(c) cacaroot/Fotolia

Challenges caused by a merger or an acquisition can be manifold, no matter whether it is your own organization that is going through M&A and the integration phase or any of your outsourcing partners or customers. Distractions or disruptions are pre-programmed and sometimes inevitable, thus, it gets hard to maintain business as usual. In such a phase it is important not to lose focus on customer relationship and ongoing projects. CHEManager International asked executives and opinion leaders in the chemical and pharmaceutical market to share their experience and advice. For instance, we wanted to know:

  • Will the consolidation in the pharmaceutical industry level off or will it even intensify?
  • Does the consolidation in the pharma industry create a necessity for CROs/CMOs to consolidate?
  • How big of an issue is a merger or an acquisition for ongoing projects?
  • How can outsourcing partners maintain their focus and guarantee confidentiality in their projects?

Read the insightful answers of the experts here

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read